COMMUNIQUÉS West-GlobeNewswire

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
02/04/2026
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/ [...]
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
02/04/2026
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. [...]
Good oral health isn't complicated — Alberta's dentists want you to know what works
02/04/2026
Simple, proven habits are still the most powerful tools for protecting your health, inside and out EDMONTON, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- Alberta's dentists have a simple message this Oral Health Month: [...]
Telix Appoints David Gill as Non-Executive Director
02/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), [...]
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
02/04/2026
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common [...]
MetaTrim BHB Claims Evaluated: The Quick Burn Keto BHB Formula Everyone is Researching, Meta Trim Ketones
02/04/2026
An informational overview of MetaTrim BHB's keto ketone salt formula, including BHB dosage research context, proprietary blend considerations, pricing structure, and key distinctions between ingredient-level findings [...]
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
01/04/2026
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
01/04/2026
Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely [...]
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
01/04/2026
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham [...]
Pennant Acquires Arbor Rose Senior Living Community in Mesa, Arizona
01/04/2026
EAGLE, Idaho, April 01, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced [...]
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01/04/2026
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 [...]
Celldex Announces Proposed Public Offering of Common Stock
01/04/2026
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of [...]
Berberine Weight Loss Patches by Purisaki Under Investigation (URGENT Warning Issued)
01/04/2026
Consumer Search Activity Surges as Questions Mount Over Berberine Patch Ingredients, Transdermal Delivery Claims, and Company Background — Publicly Available Information Compiled for 2026 Wayne, NJ, April 01, 2026 ( [...]
Herz P1 Brand Under Investigation: Review the Herz Smart Ring, P1 Smart Band & Smart P1 Body Scale Product Details
01/04/2026
A 2026 consumer overview examining Herz P1 Smart Ring tracking claims, Smart Band feature comparisons, Smart Scale accuracy context, return policy requirements, and what product information is publicly available across [...]
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
01/04/2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, [...]
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
01/04/2026
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
01/04/2026
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median [...]

Pages